CN1304442A - Protein Delivery into Eukaryotic Cells Using Recombinant Yersinia - Google Patents
Protein Delivery into Eukaryotic Cells Using Recombinant Yersinia Download PDFInfo
- Publication number
- CN1304442A CN1304442A CN99805875A CN99805875A CN1304442A CN 1304442 A CN1304442 A CN 1304442A CN 99805875 A CN99805875 A CN 99805875A CN 99805875 A CN99805875 A CN 99805875A CN 1304442 A CN1304442 A CN 1304442A
- Authority
- CN
- China
- Prior art keywords
- yersinia
- protein
- hom
- effector
- yope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to recombinant yersinia and their use to deliver proteins into eukaryotic cells, including related compositions and methods of treatment and related assays.
Description
Yersinia and protein sent the purposes that is delivered in the eukaryotic cells the present invention relates to recombinate.
Yersinia causes people and rodent disease, from enteritis and poradenolymphitis to the plague.Yersinia comprises 3 kinds: yersinia entero-colitica, and it is the kind of mankind's Yersinia the most in vogue, and it causes wide region stomach syndromes; Artificial tuberculosis yersinia genus, it causes adenositis and septicemia; And Yersinia pestis, it is the pathogenic former of the plague.
Except the route of infection difference, the kind of these three kinds of Yersinias all has people or rodent host nonspecific immune response and outgrowth resistance capacity in host's Lymphoid tissue.The pathological anatomy inspection shows be not checked through Yersinia (infect Simonet etc., (1990), immunity (Infect.Immun.) 58:841-845) in the inflammation of infection animal or parenchyma.Match with these observations in the body, Yersinia is the external phagolysis resistance of scavenger cell and polymorphonuclear leukocyte.Referring to the summary of Cornelis etc., (1997), microorganism molecules (Mol.Mierobiol) .23 (5): 861-867.Yersinia entero-colitica also has the epithelial ability that enters some cultivation, and this process is referred to as to invade (Miller etc. (1988), infection, immunity (Infect.Immun.) 56:1242-1248) usually.
Genetics research shows: the virulence of a kind of 70kb plasmid (pYV) decision Yersinia, described plasmid-encoded and regulation and control are referred to as Yops (correspondence) Yersinia outer proteins) the generation of a histone matter.These Yops form the anti-host system of integrating, and this system makes Yersinia and host cell surface born of the same parents adhere outward and then one group of sub-albumen of toxic effect injected the cytosol of host cell.Recent research further shows, a kind of so anti-host system, also be referred to as " the pathogenic son of Yersinia (virulon) ", form: (ⅰ) be exclusively used in from contact or the III type excretory system of the proteinic Ysc of being referred to as of bacterial cell secretion Yop by following 4 elements; (ⅱ) by YopB, YopD and possible other protein is LcrV being used for the one group transporter of effector protein transport to eukaryotic host cell of forming for example; (ⅲ) controlling elements and recognition system (YopN and YopG); (ⅳ) inject (or transhipment) to eukaryotic host cell and destroy one group " effector albumen " of the function of such host cell, comprise YopE, YopH, YopO/YpkA, YopM and YopP/YopJ.These gene transcription are subjected to temperature and the control that contacts both with eukaryotic cell.Summary referring to (1997) such as Cornelis.
Effector albumen destroys the function of host cell in many ways.The YopE of 23kd be the Actin muscle-microfilament structure of HeLa cell that destroy to cultivate cytotoxin (Rosquvist etc., microorganism molecules 4 (Mol.Microbiol.4), 657-667).Rosquvist etc. (1991), infection, immunity 59 (Infect.Immun.59): 4562-4569).51kdYopH is that (Hartland etc. (1994) infect the protein tyrosine phosphatase enzyme (PTP enzyme) relevant with Eukaryotic PTP enzyme that work of the tyrosine-phosphorylated protein to the scavenger cell that infects, immune 62 (Infect.Immun.62): 4445-4453).May be the consequence of this effect, YopH takes in by the scavenger cell bacterium that suppresses to cultivate and oxicracking (Rosquvist etc. (1988), infection, immunity 56 (Infect.Immun.56): 2139-2143; Bliska etc. (1995) infect. immunity 63 (Infect.Immun.63): 681-685).YopO (or YpkA) be directed eukaryotic cells the plasma membrane internal surface and may with the interactional 81kd serine/threonine kinase of the signal transduction pathway of eukaryotic cells (Hakansson etc. (1996), microorganism molecules 20 (Mol.Microbiol.20), 593-603).YopM has the acid 41kd protein that 12 rich leucines repeat motif, prompting YopM possibility bind thrombin and the platelet-mediated effect (Leung etc. (1989) that react with the interference infection, bacteriology magazine (J.Bacterial.) 171:4623-4632) .YopP relates to induce (Mills etc. (1997), periodical (Proc.Acad.Natl.Sci.USA) 94:12638-12643 of institute of NAS) of scavenger cell program death.
Having studied the proteic molecular structure of these effectors determines its secretion and transports element in needed each effector albumen.For this purpose, by merge with some reporter molecule enzyme for example the Yop effector protein gene engineering method of the different lengths of calmodulin-activated adenylate cyclase district (or Cya) brachymemma of Whooping cough bordetella (Borderella pertussis) garland cells lysin prepared hybrid protein, can detect successful secretion and/or transduction by test based on the proteic enzymic activity of reporter molecule.By using this research, Sory etc. disclose the YopE of yersinia entero-colitica and the module molecule that YopH is made up of three districts, promptly secrete needed N-end region, needed transit zone in the transporte to cells, with the terminal catalytic domain (Sory etc. of C-that are the active reason of toxic effect, (1995), institute of NAS periodical (Proc.Acad.Natl.Sci.USA) 92:11998-12002).For the YopM of yersinia entero-colitica confirmed identical district's group structure (Boland etc., (1996), EMBOJ.15:5191-5201).
The invention provides the reorganization Yersinia that is used for protein is transported to safely eukaryotic cells.Such Yersinia is not strong aspect the proteic generation power of functional effect, but has been invested function secretion and movement system.The present invention further provides and such expression vector that is used for desirable protein matter safety is transported to effectively the relevant use of mutant Yersinia of eukaryotic cells.The research not only is used to study given proteinic function, but also is used to design treatment plan.For example, can use reorganization Yersinia of the present invention with pathogenic agent protein tumor correlated albumen for example, parasite antigen or virus antigen send and are delivered to antigen-presenting cell to induce the immunne response for a kind of like this protein specific.
Carrying out property of great majority growing tumors cell may be expressed immunogenic cancer related antigen (TAAs), also is referred to as rejection antigen (TRAs).TRAs is the same with other epitope to be present in surface of tumor cells by the MHC molecule, and induces CTL to reply with external showing in vivo.Referring to, for example, Bruggen etc., (1991) Science254:1643-1647.But the tumour cell of this expression TRA does not excite the anti-tumor immune response that can control the malignant cell growth in the body reliably.Boon etc. (1992) cancer research (Cancer Surveys) 13:23-37; T.Boon (1993) Int.J.Cancer54:177-180; T.Boon (1992) cancer research progress (Advances Cancer Res.58:177-209).
Identified multiple codes for tumor rejection antigen precursor (or TRAPs) gene, they are processed into TRAs in tumour cell.The gene of such coding TRAP comprises following member: MAGE family, BAGE family, DAGE/Prame family, GAGE family, RAGE family, SMAGE family, NAG, tyrosine oxidase, Melan-A/MART-1, gp100, MUC-1, TAG-72, CA125, the proto-oncogene of sudden change is p21ras for example, and the tumor suppressor protein gene of sudden change is p53 for example, and tumour correlated virus antigen is HPV16 E7 for example.Referring to, the summary of Eynde and Bruggen (1997) for example, Curr.Opin.Immunol.9:684-693, Sahin etc. (1997) Curr.Opin.Immunol.9:709-716, with (1997) pharmacology such as Shawler progress (Advances in Pharmacology) 40:309-337, Academic Press, Inc.:San Diego.California.The evaluation of these genes makes reorganization produce TRAs or TRAPs, and they can be next as the vaccine for the treatment of various cancers.
The Yersinia that the present invention relates to recombinate is sent desirable protein matter the purposes that is delivered in the eukaryotic cells.Especially, reorganization Yersinia of the present invention is used for protein or its derivative sent and passs antigen-presenting cell.According to the present invention, antigen-presenting cell accept to send pass the back existence can be by the epitope of T cell recognition.Therefore, reorganization Yersinia of the present invention can be applied in various immunodiagnosises or the methods of treatment.
The present invention is by following openly further elaborating.
Yersinia and protein sent the purposes that is delivered in the eukaryotic cells the present invention relates to recombinate.
One embodiment of the invention provide the sub-albumen of functional effect to produce the not strong sudden change Yersinia bacterial strain of power.The present invention's Yersinia bacterial strain that preferably suddenlys change is five heavy mutants which hads of being appointed as yopEHMOP.
Another embodiment of the invention is provided for sending the expression vector of passing eukaryotic cells with heterologous protein.According to the present invention, a kind of like this expression vector is characterised in that (from 5 ' to 3 ' direction) promotor, and coding send first nucleotide sequence of delivery signal, and the coding of fusion on first nucleotide sequence will send second nucleotide sequence of the heterologous protein of passing.
According to this embodiment of the present invention, described promotor preferably be selected from Yersinia cause a disease subbase because of; More preferably, be the gene of coded actions; More preferably, be the YopE gene.Sending delivery signal is the peptide sequence that is selected from the Yersinia effector, comprises YopE, YopH, YopO/YpkA, YopM and YopP/YopJ.The delivery signal that send like this can be by secretion and the movement system identification of Yersinia.Heterologous protein of the present invention comprises naturally occurring protein or its part, for example known antigens of tumor correlated albumen or pathogenic agent.Heterologous protein of the present invention also comprises the protein of artificial design, for example proteinic fusion or the proteinic part that meets frame ground.
Another embodiment of the invention provides reorganization Yersinia, i.e. the said mutation body bacterial strain Yersinia that further transforms with expression vector of the present invention.Such reorganization Yersinia is preferred for heterologous protein sent and is delivered in the eukaryotic cells.Preferred eukaryotic cells is the antigen-presenting cell that can present the immunogenicity epi-position, and described immunogenicity epi-position is from sending the heterologous protein of passing to derive.
Another aspect of the present invention is used for relating to such reorganization Yersinia in the immunogenic composition of induce immune response (cellullar immunologic response, perhaps humoral immunoresponse(HI), perhaps both combinations) and the method.
Another aspect of the present invention can use reorganization Yersinia of the present invention in the external scheme of the validity that is used for estimating vaccination regimen.Reorganization Yersinia of the present invention can also be used in the scheme of ex vivo with generation specific CTL s with to use such CTLs to be used for the treatment of various illnesss, for example tumour or pathogenic infection.Reorganization Yersinia of the present invention is used in the scheme in vivo, promptly as recombiant vaccine, treats the patient of ill (for example tumour or pathogenic infection).
Fig. 1 illustrates the plasmid figure of expression vector pMS111-MAGE-1 (YopE130-MAGE1).
Fig. 2 (A) diagram process of human B cell (HLA-A1) the stimulation CTL82/30 that transforms with the Yersinia blended EBV-that recombinates; (B) amount of the IFN-γ of diagram activated CTLs release.
Fig. 3 illustrates the sequence of yersinia entero-colitica YopM gene.
Fig. 4 illustrates the sequence of yersinia entero-colitica YopE gene.
Fig. 5 illustrates the sequence of yersinia entero-colitica YopH gene.
Fig. 6 illustrates the sequence of yersinia entero-colitica YopP gene.
Fig. 7 illustrates the sequence of yersinia entero-colitica YopP gene.
Yersinia ruckeri and protein is sent the purposes that is delivered in eukaryotic cells the present invention relates to recombinate.
Especially, the invention provides the sub-albumen of functional effect and produce the not strong sudden change Yersinia ruckeri bacterial strain of power. The present invention further provides expression vector, in the time of in being transformed into said mutation body bacterial strain Yersinia ruckeri, the protein that its permission will be expected, for example MAGE-1 protein, send and be delivered in the eukaryotic cells human B cell that for example EBV-transforms. The invention discloses after accepting to send the protein of passing, antigen-presenting cell is processed and is sent the protein of passing, and in the situation that the MHC molecule cause for the immune response of sending the protein specific of passing, the submission antigenic epitopes. For example, after recombinating Yersinia ruckeri picked-up MAGE-1 protein from the present invention, human B cell is identified by the ctl clone for the MAGE-1 epitope specificity. Therefore, the invention provides for the protein that will expect and send the effective restructuring Yersinia ruckeri system with the toxicity that reduces that is delivered in eukaryotic cells.
Here the term that uses " Yersinia ruckeri " refers to all kinds of Yersinia, comprises yersinia enterocolitica, artificial tuberculosis yersinia genus and Yersinia pestis.
For the purposes of the present invention, the term that uses here " restructuring Yersinia ruckeri " refers to the Yersinia ruckeri that transforms with expression vector genetic engineering of the present invention.
Here the term that uses " send and passs " and refers to the protein from Yersinia ruckeri is transported to eukaryotic cells, be included in marking protein in Yersinia ruckeri, from the protein of such Yersinia ruckeri secreting, expressing with by the protein transduction that such Yersinia ruckeri will secrete, transport to the cytosol of eukaryotic cells. Therefore, " send delivery signal " and refer to the secretion of Yersinia ruckeri and peptide sequence that movement system can be identified and refer to protein is sent and passs eukaryotic cells from Yersinia ruckeri.
As used herein, " secretion " of protein refers to that such protein outwards passes through the transhipment of the cell membrane of Yersinia ruckeri. " transhipment " of protein refers to that the jump plasma membrane of eukaryotic cells of such protein send in the cytosol that is delivered to such eukaryotic cells.
Here " eukaryotic cells " that uses, the surface that Yersinia ruckeri adheres to, also be referred to as " target cell " or " target eukaryotic cells ".
One embodiment of the invention provide the sub-albumen of functional effect to produce the not strong mutant Yersinia ruckeri bacterial strain of power.
The effector albumen of Yersinia ruckeri, namely usually being transported to Yersinia ruckeri in the cytosol of the target eukaryotic cells albumen that causes a disease is virose for target cell. Therefore, " the sub-albumen of functional effect " refers to have definite catalytic activity and can excite effector albumen for the specificity toxicity of target cell.
Therefore, mutant Yersinia of the present invention is used for the toxicity to reduce, and promptly not exclusively abolishes or kill the toxicity of target cell, protein is sent pass eukaryotic cells.Pass proteinic purpose in order to send, secretion of mutant Yersinia of the present invention and movement system need be complete.
Cloned 5 effector genes from yersinia entero-colitica, they are YopE, YopH, YopO, YopM and YopP (Fig. 3-7).Cloned effector gene of equal value from artificial tuberculosis yersinia genus, respectively called after YopE, YopH, YpKA, YopM and YopJ.Some effector genes have been cloned from Yersinia pestis.The nucleotide sequence of these Yop genes is available to those skilled in the art, for example obtains from the Genebank database.
For the purposes of the present invention, with the gene of italics letter representation coded actions to be different from effector albumen.Represent mutant effector gene with lowercase.For example YopE refers to the effector albumen of YopE genes encoding.YopE represents wild type gene, and the YopE representative has the gene of sudden change.
According to the present invention, mutant Yersinia bacterial strain can be by inducing at least one sudden change to produce at least one effector encoding gene.Preferably, such effector encoding gene comprises YopE, YopH, YopH/YpkA, YopM and YopP/YopJ.The professional and technical personnel can use any standard technique to produce sudden change in these Yop genes.Sambrook etc. have described general such technology.Referring to Sambrook etc., (1989) molecular cloning: laboratory manual (Molecular Cloning:A Laboratory Manual), second edition, cold spring harbor laboratory publishes: cold spring port, New York.
Term " sudden change " is used as general terms here and comprises the variation of single base pair and a plurality of base pairs.Such sudden change can comprise replacement, phase shift mutation, disappearance and brachymemma.
According to the present invention, in the promoter region of effector encoding gene, can produce sudden change, eliminate described effector expression of gene like this.
In the coding region of effector encoding gene, also can produce sudden change, eliminate the proteic catalytic activity of effector of coding like this.Effector proteic " catalytic activity " refers to the proteic anti-target cell function of effector, i.e. toxicity.Such activity is controlled by the catalysis motif in the proteic catalytic structure of the effector district.The authentication method of effector proteic catalytic structure district and/or catalysis motif is within those skilled in the art's ken.Referring to, for example, Sory etc. (1995), (1997) such as Boland etc. (1996) and Cornels.
Therefore, a preferred embodiment of the present invention is the whole catalytic structure of disappearance district.Another kind of preferred sudden change is the phase shift mutation in the effector encoding gene, makes not have the catalytic structure district from the protein of such " frameshit " genetic expression.Most preferred sudden change is the sudden change of whole coding region disappearance.
The present invention also comprises other sudden change, for example little disappearance or the replacement of base pair, and this produces in the proteic catalysis motif of effector, causes the destruction of the given proteic catalytic activity of effector.
Available many methods import Yersinia with the sudden change that produces in the Yop group.A kind of such method relates to is cloned into the Yop gene (being the yop gene) of sudden change in " spontaneous inactivation " carrier, and it can import Yersinia by the yop gene that equipotential changes sudden change." spontaneous inactivation " carrier like this is described in (1997) microorganism molecules (Mol.Microbiol) 23:409-411 such as (1991) gene (Gene) 109:137-141 such as Kaniga and Sarker.In the method, the sudden change that a plurality of yop genes produce can import Yersinia successively, obtains multimutation reorganization Yersinia.The order that the yop sequence of these sudden changes imports is not important.
The preferred mutant Yersinia of the present invention bacterial strain is five heavy mutant Yersinia bacterial strains, and wherein all effector encoding genes suddenly change, and the Yersinia that obtains no longer produces the sub-albumen of any functional effect.For yersinia entero-colitica, five so heavy mutant Yersinia bacterial strains are labeled as yopEHOMP or are labeled as yopEHAM for artificial tuberculosis yersinia genus.An example of such yopEHOMP bacterial strain is yersinia entero-colitica MRS40 (pABL403).
Under some conditions, may expect just some rather than whole effector yop transgenations.For example, pass will point to scavenger cell the time when sending, YopH does not preferably suddenly change, because YopH is considered to by suppressing macrophage phagocytic lysis effect.(1989) such as Rosqvist etc. (1988) and Rosqvist.Therefore, the invention further relates to the multimutation Yersinia outside the five heavy mutant Yersinias, for example double mutant, triple mutant type and quadruple mutant Yersinia.
Perhaps, wherein can import by various known method for transformation (hereinafter further describing) under the five heavy mutant Y.yopEHOMP bacterial strain situations at wild-type YopH gene, five heavy mutant Yersinia bacterial strain yopEHOMP still can be used for sending of scavenger cell passed.In the method, can produce multimutation Yersinia bacterial strain, wherein Qi Wang one group of Yop gene is undergone mutation, and makes that having only protein of interest matter to send is delivered in the target cell.
Another aspect of the present invention relates to mutant Yersinia strain combinations of the present invention and is used for sending the expression vector that is delivered to eukaryotic cells with desirable protein matter.According to the present invention, a kind of like this carrier is characterised in that (from 5 ' to 3 ' direction) promotor, and coding send first nucleotide sequence of delivery signal, is fused to second nucleotide sequence that coding on first nucleotide sequence will send the heterologous protein of passing.
According to the present invention, the promotor of expression vector be preferably selected from Yersinia cause a disease subbase because of." Yersinia cause a disease subbase because of " refers to that the gene on the Yersinia pYV plasmid, its expression are subjected to temperature and the control that contacts both with target cell.Summarize referring to (1997) such as Cornelis.Such gene comprises the encoding gene (Ysc gene) of mechanism of secretion element, transporter encoding gene (YopB, YopD and LcrV), encoding gene of controlling element (YopN and LcrG) and effector encoding gene (YopE, YopH, YopO/YpKA, YopM and YopP/YopJ).
In a preferred embodiment of the invention, described promotor is selected from YopE from the effector encoding gene, YopH, YopO/YpKA, one of YopM and YopP/YopJ.More preferably, promotor is from YopE.
Further according to the present invention, coding send first dna sequence dna of delivery signal and described promotor to be operatively connected.
Above-described " sending delivery signal " thus refer to be instructed protein secreting and be transported to polypeptide in the eukaryotic cells by the identification of the secretion of Yersinia and movement system.
According to the present invention, such peptide species is selected from effector albumen.Described effector albumen comprises YopE, YopH, YopO/YpkA, YopM and YopP/YopJ.Preferably, effector albumen is YopE.More preferably, effector albumen is the YopE of yersinia entero-colitica.
Those skilled in the art are familiar with sending the authentication method of passing the proteic peptide sequence of a kind of proteinic effector.For example, Sory etc. (1994) has described a kind of like this method.In brief, peptide sequence from the proteic different piece of Yop is fused on the reporter molecule enzyme with can meeting frame, for example calmodulin-activated adenylate cyclase the district (or Cya) of Whooping cough bordetella (Bordetella pertussis) garland cells lysin.By the cyclase activity indication that in the eukaryotic cells that infects, occurs causing cAMP to accumulate the Yop-Cya hybrid protein is sent in the cytosol that is delivered to eukaryotic cells.The example that send the delivery signal polypeptide like this comprises from yersinia entero-colitica: YopE
130(terminal 130 amino acid of the N-of YopE), YopE
50, YopM
100And YopH
71
By using this research, if expectation, those skilled in the art can determine the minmal sequence that requires, and a kind of proteinic continuous amino acid sequence is passed in sending that promptly length is the shortest.Referring to, for example, Sory etc. (1994).Therefore, the present invention preferably send delivery signal to pass the proteic amino acid minmal sequence of a kind of proteinic Yop effector and form by sending at least.
Further according to the present invention, second dna sequence dna of coding heterologous protein and first dna sequence dna in the carrier of the present invention meet frame ground and merge, and are delivered in the eukaryotic cells to send.
Here employed term " heterologous protein " refers to that a kind of is not the proteic protein of Yersinia Yop." Yop albumen " refers to the excretory Yersinia sub-protein that causes a disease, and comprises transporter and effector.
According to the present invention, " a kind of heterologous protein " comprises naturally occurring protein or its part.Term " a kind of proteinic part " comprises that it is antigenic a kind of proteinic peptide or polypeptide fragment that length is enough to.Preferably, such fragment is made up of a kind of proteinic 8 or 9 amino acid at least." a kind of heterologous protein " that uses among the present invention also comprises protein or its fragment of genetically engineered preparation, for example two or more naturally occurring protein or its part, the syzygy of multi-epitope (syzygys that meet frame ground of two or more peptide epitopes), illustrated as (1995) such as Thompson at the periodical 92:5845-5849 of institute of NAS.
The first and second dna sequence dna expressed protein that merge also are referred to as " fusion rotein " or " hybrid protein ", and promptly Yersinia is sent the heterozygote of delivery signal and a kind of heterologous protein.
For sending the heterologous protein of passing not have particular determination.The present invention be more particularly directed to protein, for example known tumor correlated albumen, known pathogen antigen and cytokine.
" tumor correlated albumen " refers to a kind of protein specific expressed in tumour or a kind of protein of expressing with respect to healthy tissues abnormal level in tumour.Such tumor correlated albumen includes but not limited to following member: MAGE family, BAGE family (for example BAGE-1), DAGE/Prame family (for example DAGE-1), GAGE family, RAGE family (for example RAGE-1), SMAGE family, NAG, tyrosine oxidase, Melan-A/MART-1, gp100, MUC-1, TAG-72, CA125, the proto-oncogene of sudden change is p21ras for example, and the tumor suppressor protein gene of sudden change is p53 for example, tumour correlated virus antigen (for example HPV16 E7), HOM-MEL-40, HOM-MEL-55, NY-COL-2, HOM-HD-397, HOM-RCC-1.14, HOM-HD-21, HOM-NSCLC-11, HOM-MEL-2.4, and HOM-TES-11.The member of MAGE family includes but not limited to MAGE-1, MAGE-2, MAGE-11.The member of GAGE family includes but not limited to GAGE-1, GAGE-6.Referring to, the summary of Van den Eynde and Van denBruggen (1997) for example, Curr.Opin.Immunol.9:684-693, (1997) such as (1997) Curr.Opin.Immunol.9:709-716 such as Sahin and Shawler.These protein show relevant with some tumour, for example melanoma, lung cancer, prostate cancer, mammary cancer, colorectal carcinoma and other cancer.
Also can use from the multiple known antigens of pathogenic agent deutero-according to the present invention.The pathogenic agent that the present invention relates to comprises virus, bacterium, parasite and fungi.The former antigenic object lesson of feature that causes a disease comprises influenza virus nucleoprotein (residue 218-226, according to (1997) J.Virol.71:2715-2721 such as F.), antigen (referring to (1997) J.Virol.71:2292-2302 such as An) from parainfluenza virus and lymphocytic choriomeningitis virus, the B1 albumen of hepatitis C virus (Bruna-Romero etc. (1997) Hepatology25:470-477), the envelope glycoprotein gp160 of HIV (Achour etc. (1996) J.Virol.70:6741-6750), the 252-260 amino acids of Plasmodium berghei or circumsporozoite protein (the European Journal of Immunologies of Allsopp etc. (1996) (Eur.J.Immunol.) 26:1951-1958), A type influenza virus nucleoprotein (residue 366-374, Nomura etc. (1996) immunological method magazines (J.Immunol.Methods) 193:4149), the plain O albumen of the molten born of the same parents in the listeria bacteria of Listeria monocytogenes (residue 91-99, An etc. (1996) infect. immunity (Infect.Immun.) 64:1685-1693), people 16 type papilloma virus E6 albumen (residue 131-140, Gao etc. (1995) Journal of Immunologies (J.Immunol.) 155:5519-5526) and people 16 type papilloma virus E7 albumen (residue 21-28 and 48-55, Bauer etc. (1995) Scand.J.Immunol.42:317-323), respiratory syncytial virus (residue 82-90 and 81-95, Hsu etc. (1995) immunologys (Immunology) 85:347-350), herpes simplex virus type 1 ribonucleotide reductase (referring to (1995) J.Gen.Virol.69:1122-1131 such as Salvucci) and rotavirus VP 7 albumen (referring to (1993) J.Gen.Virol.74:2579-2586 such as Franco), P.falciparum antigen (causing malaria) and hepatitis B surface antigen (Gilbert etc. (1997) Nature Biotechnol (Nature Biotech) 15:1280-1283).
Therefore above-mentioned proteinic encoding sequence can be cloned into to be used to send in the expression vector of the present invention and pass.
Also can use the encoding sequence of multiple little antigenic peptide among the present invention.Those skilled in the art can easily determine to produce the desired segmental length of immunogenic peptide.Perhaps, the technician also can use the known encoding sequence that excites the peptide that specific T-cells replys, for example according to United States Patent (USP) 5462871, United States Patent (USP) 5558995, United States Patent (USP) 5554724, United States Patent (USP) 5585461, United States Patent (USP) 5591430, United States Patent (USP) 5554506, United States Patent (USP) 5487974, United States Patent (USP) 5530096, United States Patent (USP) 5519117 disclosed tumor associated antigen peptides (TRAs).The example of TRAs is provided in the table 1.Also referring to the summary of Eynde and (1997) such as Bruggen (1997) and Shawler.Also can use the former antigenic peptide that causes a disease, for example (1997) those disclosed such as Gilbert.
According to mentioned above, the naturally occurring proteinic encoding sequence of total length, a naturally occurring proteinic part, the perhaps combination of naturally occurring proteinic part, perhaps different naturally occurring protein or can use in the present invention from the encoding sequence of the combination of the part of different proteins.For example, can use the encoding sequence of multi-epitope, for example Thomson etc. (1995) describe those.Preferably, a kind of proteinic at least one epi-position of second dna sequence encoding of expression vector of the present invention." epi-position " refers at least 8 or 9 amino acid whose peptides.
Those skilled in the art are familiar with the technology of preparing of the dna fragmentation of an a kind of proteinic part of coding, perhaps technology that in frame a kind of DNA sequences encoding of a proteinic part is connected with the DNA sequences encoding of an another kind of proteinic part or the like.
Carrier of the present invention can comprise other sequential element, 3 ' end sequence (comprising terminator codon and polyadenylic acid sequence) for example, thus perhaps invest the gene that drug resistance has been selected the Yersinia transformant of carrier of the present invention.
Expression vector of the present invention can be transformed in the Yersinia with multiple currently known methods.For the object of the invention, the method for transformation that imports expression vector includes but not limited to electroporation, and the conversion of calcium phosphate mediation engages perhaps their combination.For example, can carrier be transformed in first bacterial isolates by the standard electric puncturing technique.Subsequently, by engaging (also being referred to as the method for " transfer ") a kind of like this carrier is transferred to the Yersinia from first bacterial isolates.Can for example select Yersinia transformant (promptly having absorbed the Yersinia of described carrier) with microbiotic.These technology are well known in the art.Referring to, for example, Sory etc. (1994).
A preferred embodiment of the present invention relates to the Yersinia that is used for above-mentioned heterologous protein is sent the said mutation body Yersinia bacterial strain of the expression vector conversion that is delivered to eukaryotic cells.
Therefore, the present invention relates to send the method that is delivered in the eukaryotic cells with above-mentioned heterologous protein.
The present invention relates to can be by the recombinate eukaryotic cells of wide region of Yersinia orientation of the present invention.
" orientation " refers to that the born of the same parents of Yersinia and eukaryotic cells adhere outward.
Especially, the present invention relates to antigen-presenting cell." antigen-presenting cell " represents at least one I class or II class MHC determinant here, and can comprise those cells that are known as sole duty (professianal) antigen-presenting cell, for example scavenger cell, dendritic cell and B cell.Other sole duty antigen-presenting cell comprises monocyte, marginarium Kupffer cell, microglia, Langerhans cell, staggered dendritic cell, follicular dendritic cell and T cell.Also can use facultative antigen-presenting cell according to the present invention.The example of facultative antigen-presenting cell comprises astroglia cell, follicular cells, and endotheliocyte and inoblast filter are as used herein, and " antigen-presenting cell " comprises full-time sexual type and facultative type antigen-presenting cell.
Also can be from from the Mammals tissue or blood (containing peripheral blood lymphocytes) the sample separation antigen-presenting cell that obtain of people or rodents for example.Also can use the clone of setting up from such sample.The method of setting up clone is well known in the art.Also can be from American type culture collection, 12301Parklawn Drive, Rockville, Maryland, 20852-1776 directly obtain some clones.Can use normal and malignant cell.
According to the preferred embodiments of the invention, the MHC determinant that antigen-presenting cell is expressed and related Mammals express those are compatible, and these MHC determinants can present one of at least one or more oneself send the epitopes of the protein derived of passing.
Those skilled in the art also be familiar with to determine the method that MHC molecule that antigen-presenting cell expresses is whether compatible with related mammalian subject, for example known HLA-type method.Referring to people's such as Coligan instruction (1994), Current Protocols in Immunology JohnWiley ﹠amp; Sons Inc: New York, New York.
The technician can determine to present special antigenic MHC molecule by a large amount of instruction in this area, and for example United States Patent (USP) 5405940 instruction is determined HLA-A1 as the MAGE-1 peptide, and EADPTGHSY presents molecule; United States Patent (USP) 5558995 instructions determine that HLA-Cw1601 is used to present another kind of MAGE-1 peptide, SAYGEPRKL; United States Patent (USP) 5530096 instruction is determined HLA-A2 as the tyrosine oxidase peptide, and MLLAVLYCL presents molecule.Do not express at the eukaryotic cells of orientation under the situation of the HLA of expectation or MHC molecule, the gene of this molecule of encoding can import eukaryotic cells by known method for transformation or transfection method.
Further according to the present invention, can realize that proteinic sending pass by making eukaryotic cells under appropriate condition, contact the reorganization Yersinia.Consider cause a disease subbase because of abduction delivering and the condition of transhipment, various references and technology are conventionally available to those skilled in the art, described condition comprises desired temperatures, Ca
++Concentration, Yersinia and target cell blended mode or the like.Referring to, for example, Cornelis, Cross talk betweenYersinia and eukaryotic cells, Society for GeneralMicrobiology Symposium, 55; MoCRAE, SAUNDERS, SMYTH, STOW (volume), the interactional molecules of host disease substance aspect (Molecular aspects of host-pathoge interactions) Cambridge University Press, 1997.Condition can change according to the type of the eukaryotic cells of wanting orientation, for example is used for the condition (Sory etc. (1994)) of directed people's epithelial cancer HeLa cell; Condition (Starnbach etc. (1994) Journal of Immunology (J, Immunol.) 153:1603) that is used for directed mouse thymus knurl or melanoma cells; The condition (Boland etc. (1996)) that is used for directed mouse macrophage.Those skilled in the art can determine such variation by routine techniques.
Those skilled in the art can also use and determine that sending of fusion rotein pass the multiple test of whether success.For example, can perhaps pass through the plain antibody test that engages of immunofluorescence with isotropic substance or the plain mark fusion rotein of immunofluorescence, J.13:964 disclosed as (1994) EMBO such as Rosqvist.Measuring also can be to send the proteinic enzymic activity of passing, for example, and the test of Sory etc. (1994) description.Measuring also can be to send the proteinic antigenicity of passing.For example, send in the human B cell that is delivered to the EBV-conversion by measuring MAGE-1 albumen to the identification of so directed B cell the CTL cell of MAGE-1 epitope specificity.Then, comprise the self-activating CTLs secretion of test I FN-γ or discharge Cr51, can measure such CTL identification from the dissolved target cell by multiple test.Also can use to resemble to use for such mensuration and anti-ly send the western blot analysis of passing proteinic specific antibody, PCR in situ hybridization, perhaps ELISPOT (MabtechAB, Sweden) such method.Referring to, for example, (1996) immunological method magazine (J.Immunol.Methods) 191:131-142 such as W.Herr etc. (1997) immunological method magazine (J.Immunol.Methods) 203:141-152 and W.Herr.
Of the present invention further aspect, use for induce immune response and protein can be sent the reorganization Yersinia of passing antigen-presenting cell.Therefore, the present invention relates to use the immunogenic composition and the method for the invention described above reorganization Yersinia inducing specific immunne response.
The immunne response that the present invention relates to comprises cellullar immunologic response (mainly cell-mediated by T) and humoral immunoresponse(HI) (mainly by antibody-mediated).These immunne responses of the general instruction of Janeway and Travers (Janeway and Travers (1996) immunology (Immunology), immunity system (Immune System in Health and Disease) in health and the disease, second edition, Garland publishes company limited: New York, New York and London) (also referring to (1997) Molecular Medicine Today3 (8) such as Tureci: 342-349).
According to this aspect of the present invention, can in multiple treatment plan or therepic use, use reorganization Yersinia inductive immunne response.For example, can be used for monitoring Mammals for example the in vitro method of the validity of people or rodents inoculation treatment use the reorganization Yersinia.In this scheme, from immunoprophylaxis originality composition for example the receptor of specific antigen obtain some antigen-presenting cell (for example dendritic cell).Then this antigen-presenting cell is passed the antigenic reorganization Yersinia that is used to inoculate and contacted with sending.Then, add to the mixture of antigen-presenting cell and Yersinia and to obtain peripheral blood lymphocyte (promptly from body PBLs) from identical receptor, described from identical receptor obtain peripheral blood lymphocyte preferably with for example IL-2 combination of cytokine.Contact antigen and then successively behind the booster immunization by CTLs or estimate the validity of inoculation for the existence of the antibody of correlation antigen specific.Use standard testing, for example Cr51 discharges test or γ-IFN secretes test, the existence of antigen measuring specific CTL s.By resembling the standard hyperplasia test of using the such test of the antigenic ELISA be fixed on the culture plate or being used for the T-helper, can measure the existence of specific antibody.
Being used for inducing for a kind of protein is that the scheme of the ex vivo of specific CTLs also can be used the reorganization Yersinia.The method of the specific CTL s that external generation is such is well known in the art, and is for example disclosed as United States Patent (USP) 5342774.In brief, obtain the blood sample that contains the T cell precursors from Mammals.Stimulator cell incubation from this blood sample purifying PBLs and the antigenic epitopes with expressing MHC.Secrete test by for example Cr51 release test or γ-IFN, can detect this epitope specificity CTLs of generation.
According to the present invention, the mixture of reorganization Yersinia and antigen-presenting cell can be used as " stimulator cell " being used for producing the in vitro method of waiting to send the protein specific CTLs that passs.The expressed MHC determinant of the MHC determinant that employed antigen-presenting cell is expressed and the Mammals that therefrom separates PBLs is compatible, and at least one of these MHC molecules can be and pass T cell, and one or more epi-positions from protein derived are sent to pass.The CTL cell of Chan Shenging can impose on the treatment plan of adoptive transfer and suffer from the Mammals that is characterised in that the symptom of sending the protein unconventionality expression that uses in the delivery system like this.For adoptive transfer, referring to following instruction: Greenberg (1986) Journal of Immunology (J.Immunol.) 136 (5): 1917; Riddel etc., (1992) Science257:238; The European Journal of Immunologies of Lynch etc. (1991) (Eur.J.Immunol.) 21:1403; With (1989) cell (Cell) 59:603 such as Kast.CTLs can alleviate or treat illness, for example tumour, parasitic infection or virus infection by this antigenic cell of dissolving unconventionality expression.
Therefore, the present invention relates to sanatory method and composition.The illness that the present invention relates to comprises tumour and pathogenic agent for example bacterium, parasite, fungi or virus infection.
" treatment " refers to alleviate or suppress illness, for example suppresses tumor growth or transfer, reduces the tumour size, perhaps alleviates the pathogenic infection symptom.
Reorganization Yersinia of the present invention also can be used in vivo, and the Yersinia that is about to recombinate is introduced Mammals for example in people or the rodents recipient's body.
For using reorganization Yersinia, test safety in animal before use in the body.In this case, can go in the stomach animal administered recombinant Yersinia by oral or direct clothes.Several days (1-3 days) can kill animals behind the administered recombinant Yersinia.Intestinal lavage and to the Yersinia of aggregate lymphatic nodule or movement inspection survival.Referring to, for example Sory etc. (1992) infects.Immunity. (Infect.Immun.) 60:3830-3836.Can also be by peritoneal injection to animal administered recombinant Yersinia.Can be to the existence of organizing Yersinia in for example kidney and hepatoscopy cell of the animal that kills, this is the indication of enough securities not.Can by for example on solid medium the culturing cell extract detect Yersinia in the cell.Referring to (1988) Microb.Pathogen4:431-442. such as Sory
Can be in immunogenic composition reorganization Yersinia safe in utilization come the immunne response of the various illnesss of inductive treatment Mammals.The illness that the present invention relates to comprises tumour and pathogenic infection, as disclosed herein.
Described immunogenic composition can comprise other material except the reorganization Yersinia, for example cytokine, adjuvant and pharmaceutical acceptable carrier.Also can comprise cytokine in for example such immunogenic composition, use can be sent the present invention of the delivery cell factor other reorganization Yersinia.
These immunogenic compositions can be administered to the receptor with any usual manner, and are for example oral, intraperitoneal, intravenously or subcutaneous.Such composition inductive specific immune response can cause mediation or the antibody-mediated cell that kills and wounds pathogenic agent or related antigen unconventionality expression of CTL-, alleviates relevant illness like this.
The present invention describes in further detail by the following examples.
All publications of mentioning in this specification sheets are incorporated by reference here.Term that uses in this specification sheets and expression are as term rather than the restriction described, do not mean that and use such term and express shown in the eliminating or Equivalent or its part of described character, be appreciated that various within the scope of the present invention changes are possible.
Bacterial isolates, plasmid and growth conditions
Use yersinia entero-colitica belong to E40 (pYV40) (referring to, M.P.Sory etc. (1995) " use cyaA gene fusion method; identify secretion and internalization desired YopE and YopH district in the scavenger cell colloidal sol ", and institute of NAS prints 92:11998-12002), it is homogenic responsive derivative MRS40 (pYV40) (referring to M.R.Sarker etc.) and their various nonpolar mutant.Listed plasmid in the table 1.Cell is brain heart infusion (BHI) (Difco, Destroit, Michigan) the middle cultivation.Spend the night after pre-the cultivation, dilute 1/20 bacterium, make and at room temperature grow 30 minutes, and before infection, under 37 ℃, hatch and induced Yop to cause a disease synthesizing of son in 150 minutes with fresh BHI.
Table 1: the antigen of giving an example
| Gene | ????MHC | ????peptide | The position | ?SEQ?ID ???NO： |
| ???MAGE-1 | ???HLA-A1 | ???EADPTGHSY | ???161-169 | ???1 |
| ??HLA-Cw16 | ???SAYGEPRKL | ???230-238 | ???2 | |
| ???MAGE-?3 | ???HLA-A1 | ???EVDPIGHLY | ???168-176 | ???3 |
| ???HLA-A2 | ???FLWGPRALV | ???271-279 | ???4 | |
| ???HLA-B44 | ??MEVDPIGHLY | ???167-176 | ???5 | |
| ?????BAGE | ??HLA-Cw16 | ???AARAVFLAL | ????2-10 | ???6 |
| ???GAGE-1,2 | ??HLA-Cw16 | ????YRPRPRRY | ????9-16 | ???7 |
| ?????RAGE | ???HLA-B7 | ??SPSSNRIRNT | ????11-20 | ???8 |
| ?????GnT-V | ???HLA-A2 | ??VLPDVFIRC(V) | ???2-10/11 | ???9 |
| ?????MUM-1 | ???HLA-B44 | ????EEKLIVVLF | Exon 2/interior apparent son | ??10 |
| EEKLSVVLF (wild-type) | ??11 | |||
| ?????CDK4 | ???HLA-A2 | ???ACDPHSGHFV | ????23-32 | ??12 |
| ARDPHSGHFV (wild-type) | ??13 | |||
| Beta-catenin is white | ???HLA-A24 | ???SYLDSGIHF | ????29-37 | ???14 |
| ???SYLDSGIHS ???(wild?type) | ???15 | |||
| Tyrosine oxidase | ???HLA-A2 | ???MLLAVLYCL | ????1-9 | ???16 |
| ???HLA-A2 | ???YMNGTMSQV | ??369-377 | ???17 | |
| ???HLA-A2 | ????YMDGTMSQV | ??369-377 | ???18 | |
| ???HLA-A24 | ???AFLPWHRLF | ??206-214 | ???19 |
| HLA-B44 | ?SEIWRDIDF | 192-200 | 20 | |
| HLA-B44 | ?YEIWRDIDF | 192-200 | 21 | |
| HLA-DR4 | ?QNILLSNAPLGPQ ?FP | 56-70 | 22 | |
| HLA-DR4 | ?DYSYLQDSDPDSF ?QD | 448-462 | 23 | |
| Melan-A MAHT-1 | HLA-A2 | (E)AAGIGILTV | 26/27-35 | 24 |
| HLA-A2 | ILTVILGVL | 32-40 | 25 | |
| gp100 Pmell17 | HLA-A2 | KTWGQYWQV | 154-162 | 26 |
| HLA-A2 | ITDQVPFSV | 209-217 | 27 | |
| HLA-A2 | YLEPGPVTA | 280-288 | 28 | |
| HLA-A2 | LLDGTATLRL | 457-466 | 29 | |
| HLA-A2 | VLYRYGSFSV | 476-485 | 30 | |
| DAGE | HLA-A24 | LYVDSLFFL | 301-309 | 31 |
| MAGE-6 | HLA-Cw16 | KISGGPRISYPL | 292-303 | 32 |
Embodiment 2
The structure of multimutation bacterial strain
In order to make up yopHOPEM multimutation bacterial strain, reject YopE successively by using spontaneous inactivation carrier pMRS101 and the pKNG101 allelotrope exchange in the MRS40 bacterial strain, YopH, YopO, YopM and YopP gene (referring to (1997) " the improvement text that is used for the spontaneous inactivation carrier pKNG101 of gram negative bacterium gene substitution " microorganism molecules (Mol.Microbiol.) 23:409-411 such as (1991) such as K.Kaniga " be used for improving the spontaneous inactivation carrier of the wide host range of gram negative bacterium reverse genetic: the deactivation of the blaA gene that yersinia entero-colitica belongs to " Gene109:137-141 and M.R.Sarker).In the table 2 in " spontaneous inactivation carrier and mutator gene " part various disappearances have been described.Use mutator gene pPW52 (referring to (1993) such as P.Wattiau " SycE; the class chaperone albumen that the yersinia entero-colitica that relates in the secretion of YopE belongs to " " microorganism molecules (Mol.Microbiol.) 8:123-131) the YopE gene that at first suddenlys change, obtain bacterial strain MRS40 (pAB4052).With mutator gene pAB31 (referring to, S.D.Mills etc. (1997) " desired and relate to the method for YopP by function III type secretion and transhipment mechanism; that yersinia entero-colitica belongs to the apoptosis of inducing in the scavenger cell; suppose that the sub-albumen of action effect works " institute of NAS prints 94:12638-12643) YopH gene in this bacterial strain that suddenlys change, obtain dual yopEH mutant MRS40 (pAB404).Use mutator gene pAB34 (referring to, S.D.Mills etc. (1997)) to change then and obtain triple yopEHO mutant MRS40 (pAB405) by equipotential.Use mutator gene pMSK7 (referring to, S.D.Mills etc. (1997)) sudden change YopP gene then, obtain yopEHOP mutant MRS40 (pMSK46).Use YopM mutator gene pAB38 (referring to, S.D.Mills etc. (l997)) to change at last and obtain yopHOPEM bacterial strain MRS40 (pABL403) by equipotential.
Table 2: plasmid
| Plasmid | Correlated characteristic | Reference |
| pYV | ||
| pABL403 | ?pYV40?yopE 21,yopHΔ 1-352yopOΔ 65-558,yopP 23,yopM 23 | Embodiment 2 referring to this specification sheets |
| Spontaneous inactivation carrier and mutator gene | ||
| pKNG101 | oriR6K sacBR+ onTRK2 strAB+ | K.Kaniga etc. (1991) Gene109:137-141. |
| pMRS101 | oriR6K sacBR+ onTRK2 strAB+ ociColEl bla+ | M.R.sarker and G.R. Cornelis (1997) Mol. Microbiol.23:409-411. |
| pAB31 | pMRS101?yopHΔ 1-152+ | S.D.Mills etc. (1997) Proc.Natl.Acad.Sci. USA 94:12638-12643. |
| pAB34 | pMRS101?yopOΔ 65-558+??? | S.D.Mills etc. (1997) |
| pAB38 | pMRS101?yopM 23+ | S.D.Mills etc. (1997) |
| pMSK7 | pMRS101?yopP 23+ | S.D.Mills etc. (1997) |
| pPWS2 | pKNG101?yopE 21+ | P.Waattian and G.R. Cornelis (1993) Mol. Microbiol.8:123-131. |
Embodiment 3
Make up coding YopE
130The plasmid of-MAGE-1 and this plasmid imported Yersinia
Sequence to coded protein MAGE-1 meets 130 amino acid whose YopE that contain YopE that frame ground inserts the coding brachymemma, YopE
130Sequence.Such plasmid illustrates in Fig. 1 and provides.
(California) middle clone's MAGE-1cDNA is as the open reading-frame (ORF) of template by pcr amplification MAGE-1 for Invitrogen, Carlsbad to use pcDNAI/Amp.Upstream primer, AAACTGCAGATGTCTCTTGAGCAGAGGAGTC is made up of the preceding Nucleotide of the open reading-frame (ORF) that is positioned at Pst I site MAGE-1 before.Downstream primer, AAACTGCAGTCAGACTCCCTCTTCCTCCTC is made up of the then back Nucleotide complementary Nucleotide of the open reading-frame (ORF) of the MAGE-1 in Pst I site.The YopE (referring to, Sory etc. (1994) microorganism molecules (Molecular Microbiology) 14:583-594) that meets the insertion brachymemma of frame ground with Pst I digestion PCR product and in the Pst of carrier pMS111 I site.Bacterial isolates DH5 α F ' IQ electroporation is imported pMS111-MAGE-1.From some DNA that clones extracting DNA and bacterial isolates SM10 electroporation is imported positive recombinant clone.Behind SM10 (pABL403) the transfer pMS111 of Yersinia MRS40, be supplemented with nalidixic acid, select recombinant clone in the substratum that contains agar of Sodium metaarsenite and paraxin.MRS40 is the gene derivative such as grade (referring to the periodical 92:11998-12002 of institutes of (1995) NAS such as Sory) to amp-S E40.
Embodiment 4
The B cell that directed EBV-transforms
Under 28 ℃, be supplemented with nalidixic acid then, will containing clone's overnight incubation of the Yersinia MSR40 (pABL403) of pMS111-MAGE-1 in the LB substratum of m-Sodium metaarsenite and paraxin.In order to obtain 0.2 OD (optical density(OD)), in fresh culture, dilute overnight culture.The fresh culture thing increased about 2 hours down at 28 ℃.Bacterium in 0.9%NaCl, makes every milliliter to have 10 with 0.9%NaCl flushing and resuspending
8Individual bacterium.The HLA-Al+B cell that 50000EBV-transforms is placed in the micropore (96 round bottom hole) and is centrifuged into the ball shape.The reject supernatant liquor, and (culture medium supplemented has 10%FCS and is supplemented with L-arginine (116 mg/ml) the various dilutions of adding bacterium in the complete RPMI1640 of 100 microlitres, altheine (36 mg/ml), L-glutaminate (216 mg/ml)).Infect after 2 hours, add gentamicin (30 mcg/ml) insulation 2 hours, clean cell at last three times.
As negative control, also infect identical cell with the Yersinia MRS40 (pABL403) that contains pMS621, pMS621 is that only the encode YopE of brachymemma is YopE
130Plasmid.
Embodiment 5
MZ2-CTL82/30 is to the identification of the B cell of orientation
The MAGE-1 peptide EADPTGHSY that MZ2-CTL82/30 presents for HLA-A1 is specific (United States Patent (USP) 5342774).(be supplemented with 10% human serum at final volume 100 microlitre IScove ' s perfect mediums, L-arginine (116 mg/ml), altheine (36 mg/ml), L-glutaminate (216 mg/ml), Streptomycin sulphate (0.1 mg/ml), penicillin (200U/ milliliter), IL-2 (25U/ milliliter) and gentamicin (15 mcg/ml)) in contain in each micropore of Yersinia and add 5000 MZ2-CTL82/30 cells.After the incubated overnight, (Biosource, Fleurus Belgium) analyze exist (being produced by CTL during activation) of γ-IFN in the coculture supernatant liquor with standard ELISA test.Fig. 2 A illustrates a kind of like this method.
Shown in Fig. 2 B, CTL82/30 recognition coding YopE
130The HLA-A1 that-MAGE-1 Yersinia infects
+The B cell, and use control plasmid YopE
130The identical cell that infects is quite different.The optimum concn of bacterium is about 1000000 of every micropores.
Sequence table＜110〉van der Bruggen, Pierre
Cornelis, Guy R.＜120〉with the reorganization Yersinia protein is sent be delivered in the eukaryotic cells＜130〉11154＜140〉US 09/036,582＜141〉1998-03-06＜160〉39＜170〉PatentIn Ver.2.0＜210 1＜211〉9＜212〉PRT＜213〉people MAGE-1 peptide＜400 1Glu Ala Asp Pro Thr Gly His Ser Tyr
5＜210〉2＜211〉9＜212〉PRT＜213〉people MAGE-1 peptide＜400〉2Ser Ala Tyr Gly Glu pro Arg Lys Leu
5＜210〉3＜211〉9＜212〉PRT＜213〉people MAGE-3 peptide＜400〉3Glu Val Asp pro Ile Gly His Leu Tyr
5＜210〉4＜211〉9＜212〉PRT＜213〉people MAGE-3 peptide＜400〉4Phe Leu Trp Gly Pro Arg Ala Leu Val
5＜210〉5＜211〉10＜212〉PRT＜213〉people MAGE-3 peptide＜400〉5Met Glu Val Asp Pro Ile Gly His Leu Tyr
5 10＜210〉6＜211〉9＜212〉PRT＜213〉people BAGE peptide＜400〉6Ala Ala Arg Ala Val Phe Leu Ala Leu
5＜210〉7＜211〉8＜212〉PRT＜213〉people GAGE-1,2 peptides＜400〉7Tyr Arg Pro Arg Pro Arg Arg Tyr
5＜210〉8＜211〉10＜212〉PRT＜213〉people RAGE peptide＜400〉8Ser Pro Ser Ser Asn Arg Ile Arg Asn Thr
5 10＜210〉9＜211〉10＜212〉PRT＜213〉people GnT-V peptide＜400〉9Val Leu Pro Asp Val Phe Ile Arg Cys Val
5 10＜210〉10＜211〉9＜212〉PRT＜213〉people MUM-1 peptide＜400〉10Glu Glu Lys Leu Ile Val Val Leu Phe
5＜210〉11＜211〉9＜212〉PRT＜213〉people MuM-1 peptide＜400〉11Glu Glu Lys Leu Ser Val Val Leu Phe
5＜210〉12＜211〉10＜212〉PRT＜213〉people CDK4 peptide＜400〉12Ala Cys Asp Pro His Ser Gly His Phe Val
5 10＜210〉13＜211〉10＜212〉PRT＜213〉people CDK4 peptide＜400〉13Ala Arg Asp Pro His Ser Gly His Phe Val
5 10＜210〉14＜211〉the white peptide of 9＜212〉PRT＜213〉people beta-catenins＜400〉14Ser Tyr Leu Asp Ser Gly Ile His Phe
5＜210〉15＜211〉the white peptide of 9＜212〉PRT＜213〉people beta-catenins＜400〉15 Ser Tyr Leu Asp Ser Gly Ile His Ser
5＜210〉16＜211〉9＜212〉PRT＜213〉human tyrosinase peptide＜400〉16Met Leu Leu Ala Val Leu Tyr Cys Leu
5＜210〉17＜211〉9＜212〉PRT＜213〉human tyrosinase peptide＜400〉17Tyr Met Asn Gly Thr Met Ser Gln Val
5＜210〉18＜211〉9＜212〉PRT＜213〉human tyrosinase peptide＜400〉18Tyr Met Asp Gly Thr Met Ser Gln Val
5＜210〉19＜211〉9＜212〉PRT＜213〉human tyrosinase peptide＜400〉19Ala Phe Leu Pro Trp His Arg Leu Phe
5＜210〉20＜211〉9＜212〉PRT＜213〉human tyrosinase peptide＜400〉20Ser Glu Ile Trp Arg Asp Ile Asp Phe
5＜210〉21＜211〉9＜212〉PRT＜213〉human tyrosinase peptide＜400〉21Tyr Glu Ile Trp Arg Asp Ile Asp Phe＜210〉22＜211〉15＜212〉PRT＜213〉human tyrosinase peptide＜400〉22Gln Asn Ile Leu Leu Ser Asn Ala Pro Leu Gly Pro Gln Phe Pro
5 10 15＜210〉23＜211〉15＜212〉PRT＜213〉human tyrosinase peptide＜400〉23Asp Tyr Ser Tyr Leu Gln Asp Ser Asp Pro Asp Ser Phe Gln Asp
5 10 15＜210〉24＜211〉10＜212〉PRT＜213〉people Melan-A
MART-1Peptide＜400〉24Glu Ala Ala Gly Ile Gly Ile Leu Thr Val
5 10＜210〉25＜211〉9＜212〉PRT＜213〉people Melan-A
MART-1Peptide＜400〉25Ile Leu Thr Val Ile Leu Gly Val Leu
5＜210〉26＜211〉9＜212〉PRT＜213〉people gp100
Pmell17Peptide＜400〉26Lys Thr Trp Gly Gln Tyr Trp Gln Val
5＜210〉27＜211〉9＜212〉PRT＜213〉people gp100
Pmell17Peptide＜400〉27Ile Thr Asp Gln Val Pro Phe Ser Val
5＜210〉28＜211〉9＜212〉PRT＜213〉people gp100
Pmell17Peptide＜400〉28Tyr Leu Glu Pro Gly Pro Val Thr Ala
5＜210〉29＜211〉10＜212〉PRT＜213〉people gp100
Pmell17Peptide＜400〉29Leu Leu Asp Gly Thr Ala Thr Leu Arg Leu
5 10＜210〉30＜211〉10＜212〉PRT＜213〉people gp100
Pmell17Peptide＜400〉30Val Leu Tyr Arg Tyr Gly Ser Phe Ser Val
5 10＜210〉31＜211〉9＜212〉PRT＜213〉people DAGE peptide＜400〉31Leu Tyr Val Asp Ser Leu Phe Phe Leu
5＜210〉32＜211〉12＜212〉PRT＜213〉people MAGE-6 peptide＜400〉32Lys Ile Ser Gly Gly Pro Arg Ile Ser Tyr Pro Leu
510
<210> 33
<211> 1330
<212> DNA
<213> Yersinia bacteria
<400> 33
AAAAATGGCC AAAAACTTTC AATGGTAGAA GAGCTAAATT TGGATAAGTA ACGCATAAAA 60
ATTTTCGACG AAAAACTATA TATATATATA TATTTAATAT GTATGGTTTC ATTTGCAATG 120
AAAAAACCGA TAATAAAGAT ATTTTCAGAA AGGCATTCAA TATGTTTATA AACCCAAGAA 180
ATGTATCTAA TACTTTTTTG CAAGAACCAT TACGTCATTC TTCTGATTTA ACTGAGATGC 240
CAGTTGAGGC AGAAAATGTT AAATCTAAGG CTGAATATTA TAATGCATGG TCGGAATGGG 300
AACGAAATGC CCCTCCGGGG AATGGTGAAC AGAGGGGAAT GGCGGTTTCA AGGTTACGCG 360
ATTGCCTGGA CCGACAAGCC CATGAGCTAG AACTAAATAA TCTGGGGCTG AGTTCTTTGC 420
CGGAATTACC TCCGCATTTA GAGAGTTTAG TGGCGTCATG TAATTCTCTT ACAGAATTAC 480
CGGAATTGCC GCAGAGCCTG AAATCACTTC AAGTTGATAA TAACAATCTC AAGGCATTAT 540
CCGATTTACC TCCTTTACTG GAATATTTAG GTGCCGCTAA TAATCAGCTG GAAGAATTAC 600
CAGAGTTGCA AAACTCGTCC TTCTTGACAT CTATTGATGT TGATAACAAT TCACTGAAAA 660
CATTACCTGA TTTACCTCCT TCACTGGAAT TTCTTGCTGC TGGTAATAAT CAGCTGGAAG 720
AATTGTCAGA GTTGCAAAAC TTGCCCTTCT TGACTGCGAT TTATGCTGAT AACAATTCAC 780
TGAAAACATT ACCCGATTTA CCCCCTTCCC TGAAAACACT TAATGTCAGA GAAAATTATT 840
TAACTGATCT GCCAGAATTA CCGCAGAGTT TAACCTTCTT AGATGTTTCT GATAATATTT 900
TTTCTGGATT ATCGGAATTG CCACCAAACT TGTATAATCT CAATGCATCC AGCAATGAAA 960
TAAGATCTTT ATGCGATTTA CCCCCTTCAC TGGTAGAACT TGATGTCAGA GATAATCAGT 1020
TGATCGAACT GCCAGCGTTA CCTCCACGCT TAGAACGTTT AATCGCTTCA TTTAATCATC 1080
TTGCTGAAGT ACCTGAATTG CCGCAAAACC TGAAACTGCT CCACGTAGAG TACAACGCTC 1140
TGAGAGAGTT TCCCGATATA CCTGAGTCAG TGGAAGATCT TCGGATGGAC TCTGAACGTG 1200
TAATTGATCC ATATGAATTT GCTCATGAGA CTATAGACAA ACTTGAAGAT GATGTATTTG 1260
AGTAGTGCGC AAGAGCGTTC ATAATTCTGC GTCACGTTAA AATATCATTA CAACGTAATC 1320
ACTTTATCGA 1330
<210> 34
<211> 1152
<212> DNA
<213> Yersinia bacteria
<400> 34
GAATTCCCCA ACTTTGACAC CGATAACCGG TTCAATAGTA TCTGGAATAG ACAGCGAAAG 60
TTGTTGAAAT AATTGAGTGA TAGCTTGTTC AAATGAATAC ATTTGATCTC CTAATAGTTA 120
GATAAAATAT CAACTTAACC AAAGCACTCT CGGCAGACCA TCAATTTTAG CCTATAATTT 180
TTAGTTTTTA TTTTGTCTAA TATAACAACA AAAACAGCAG CGGTTTTTTA TATAACCACC 240
GGCTATTTTC CCACTAAGAT AACCTTGTTT TAATAGCCAA GGGAATAAAT AGTCATGAAA 300
ATATCATCAT TTATTTCTAC ATCACTGCCC CTGCCGGCAT CAGTGTCAGG ATCTAGCAGC 360
GTAGGAGAAA TGTCTGGGCG CTCAGTCTCA CAGCAAAAAA GTGATCAATA TGCAAACAAT 420
CTGGCCGGGC GCACTGAAAG CCCTCAGGGT TCCAGCTTAG CCAGCCGTAT CATTGAGAGG 480
TTATCATCAA TGGCCCACTC TGTGATTGGA TTTATCCAAC GCATGTTCTC GGAGGGGAGC 540
CATAAACCGG TGGTGACACC AGCACTCACG CCTGCACAAA TGCCAAGCCC TACGTCTTTC 600
AGTGATAGTA TCAAGCAACT TGCTGCTGAG ACGCTGCCAA AATACATGCA GCAGTTGAGT 660
AGCTTGGATG CAGAGACGCT GCAGAAAAAT CATGACCAGT TCGCCACGGG CAGCGGCCCT 720
CTTCGTGCCA GTATCACTCA ATGCCAAGGG CTGATGCAGT TTTGTGGTGG GGAATTGCAA 780
GCTGAGGCCA GTGCCATTTT AAACACGCCT GTTTGTGGTA TTCCCTTCTC GCAGTGGGGA 840
ACTGTTGGTG GGGCGGCCAG CGCGTACGTC GCCAGTGGCG TTGATCTAAC GCAGGCAGCA 900
AATGAGATCA AAGGGCTGGG GCAACAGATG CAGCAATTAC TGTCATTGAT GTGATATGGA 960
TAAAAACAAG GGGGTAGTGT TTCCCCCTTT TTCTATCAAT ATTGCGAATA TCTTCGTCCC 1020
TGATCTTTCA GGGGCGAATC GTTTTTTAGC ATGCTCATTG TTAGAATTTC TGACTTATCT 1080
CTCTTCTGTA TTACTACTCA TACTCTGGAA AATCCTGAGC ATTTATATCT ATGGATTGAT 1140
GCAGCACTCG AG 1152
<210> 35
<211> 1990
<212> DNA
<213> Yersinia bacteria
<400> 35
AGGGCATTGG AATTAAAAAT ATATTTATCT AAATGATGAT GAGTTTAAAT TACATTTGCC 60
TATTAAAATG AATAACGCAT TATTAACGTA TTACCATCTG TTCCCGCTTA ATTTTTTAAA 120
AAATTTAAGG TAACAATGAG TATATATCTT ATGGGAAAAG CCAAAAAACT AACGAACACT 180
ATAATAATTC GATTAACATC AATGAAAATA CACGGCTCAC CTATTATTAA AATAATACGA 240
CTAGCATTAT AAGAAAAAAT ATTTTTTATG TTTATAGTAT AGGCGTGTAT TTAATTAGTT 300
CTTAATTTAA TTAAGGAGGG AAGCATGAAC TTATCATTAA GCGATCTTCA TCGTCAGGTA 360
TCTCGATTGG TGCAGCAAGA GAGCGGTGAT TGTACCGGGA AATTAAGAGG TAACGTTGCT 420
GCCAATAAAG AAACTACCTT TCAAGGTTTG ACCATAGCCA GTGGTGCCAG AGAGTCAGAA 480
AAAGTATTTG CTCAAACTGT ACTAAGCCAC GTAGCAAATA TTGTTCTAAC TCAAGAAGAT 540
ACCGCTAAGC TATTGCAAAG CACGGTAAAG CATAATTTGA ATAATTATGA ATTAAGAAGT 600
GTCGGCAATG GTAATAGTGT ACTTGTCAGT TTACGTAGTG ACCAAATGAC ACTACAAGAC 660
GCCAAAGTGC TGTTGGAGGC TGCATTGCGA CAAGAGTCGG GAGCGAGGGG GCATGTATCA 720
TCTCATTCAC ATTCAGTCCT TCACGCACCG GGAACCCCGG TGCGTGAAGG ACTGCGTTCA 780
CATCTAGACC CCAGAACACC ACCGTTGCCA CCGCCTGAAC GACCACACAC TTCTGGCCAT 840
CACGGGGCTG GCGAAGCCAG AGCCACCGCA CCAAGCACTG TTTCTCCTTA TGGCCCAGAA 900
GCGCGCGCAG AACTCAGCAG CCGCCTCACC ACATTGCGCA ATACGCTGGC GCCAGCAACG 960
AATGATCCGC GTTACTTACA AGCCTGCGGC GGTGAAAAGC TAAACCGATT TAGAGATATT 1020
CAATGCTGTC GGCAAACCGC AGTACGCGCC GATCTTAATG CCAATTACAT CCAGGTCGGT 1080
AACACTCGTA CCATAGCGTG CCAGTATCCG CTACAATCTC AACTTGAAAG CCATTTCCGT 1140
ATGCTGGCAG AAAACCGAAC GCCAGTGTTG GCTGTTTTAG CGTCCAGTTC TGAGATAGCC 1200
AATCAAAGAT TCGGTATGCC AGATTATTTC CGCCAGAGTC GTACCTATGG CAGTATCACT 1260
GTAGAGTCTA AAATGACTCA GCAAGTTGGT CTCGGTGACG GGATTATGGC AGATATGTAT 1320
ACTTTAACGA TTCGTGAAGC GGGTCAAAAA ACAATTTCTG TTCCTGTGGT TCATGTTGGC 1380
AATTGGCCCG ATCAGACCGC AGTCAGCTCT GAAGTTACCA AGGCACTCGC TTCACTGGTA 1440
GATCAAACAG CAGAAACAAA ACGCAATATG TATGAAAGCA AAGGAAGTTC AGCGGTAGCA 1500
GATGACTCCA AATTACGGCC GGTAATACAT TGCCGTGCGG GTGTTGGCCG TACTGCGCAA 1560
CTGATTGGCG CAATGTGCAT GAATGATAGT CGTAATAGTC AGTTAAGCGT AGAAGATATG 1620
GTCAGCCAAA TGCGAGTACA AAGAAATGGT ATTATGGTAC AAAAAGATGA GCAACTTGAT 1680
GTTCTGATTA AGTTGGCTGA AGGACAAGGG CGACCATTAT TAAATAGCTA ATGTAAATAT 1740
TTATTCCTAT GAGTAAATAA AATTACTAAG AGATATACAC CACTTTGCCA ATCAAAGAAA 1800
CTTTAAACCT CAACTAAAGT AAGCAATTAG TTGAGGTTTA TCTGCTATAG AATAATTATT 1860
AACAAAAATA TAAACAACAA AATTAAAAGT TATGTGTCTA CTTTTACTTT ATGTAACCAA 1920
ACCCATTAAT GGATACCGTA CGTTTTTCTT TTATAGAATT AAACCAGTAA ATGAGATGAT 1980
GAAGGACGAT GATCATCGTC 1990
<210> 36
<211> 867
<212> DNA
<213> Yersinia bacteria
<400> 36
ATGATTGGGC CAATATCACA AATAAACAGC TTCGGTGGCT TATCAGAAAA AGAGACCCGT 60
TCTTTAATCA GTAATGAAGA GCTTAAAAAT ATCATAATAC AGTTGGAAAC TGATATAGCG 120
GATGGATCCT GGTTCCATAA AAATTATTCA CGCCTGGATA TAGAAGTCAT GCCCGCATTA 180
GTAATTCAGG CGAACAATAA ATATCCGGAA ATGAATCTTA ATTTTGTTAC ATCTCCCCAG 240
GACCTTTCGA TAGAAATAAA AAATGTCATA GAAAATGGAG TTGGATCTTC CCGCTTCATA 300
ATTAACATGG GGGAGGGTGG AATACATTTC AGTGTAATTG ATTACAAACA TATAAATGGG 360
AAAACATCTC TGATATTATT TGAACCAGTA AACTTTAATA GTATGGGGCC AGCGATACTG 420
GCAATAAGTA CAAAAACGGC CATTGAACGT TATCAATTAC CTGATTGCCA TTTTTCCATG 480
GTGGAAATGG ATATTCAGCG AAGCTCATCT GAATGTGGTA TTTTTAGTTT GGCACTGGCA 540
AAAAAACTTT ACACCGAGAG AGATAGCCTG TTGAAAATAC ATGAAGATAA TATAAAAGGT 600
ATATTAAGTG ATAGTGAAAA TCCTTTACCC CACAATAAGT TGGATCCGTA TCTCCCGGTA 660
ACTTTTTACA AACATACTCA AGGTAAAAAA CGTCTTAATG AATATTTAAA TACTAACCCG 720
CAGGGAGTTG GTACTGTTGT TAACAAAAAA AATGAAACCA TCTTTAATAG GTTTGATAAC 780
AATAAATCCA TTATAGATGG AAAGGAATTA TCAGTTTCGG TACATAAAAA GAGAATAGCT 840
GAATATAAAA CACTTCTCAA AGTATAA 867
<210> 37
<211> 2190
<212> DNA
<213> Yersinia bacteria
<400> 37
ATGAAAATCA TGGGAACTAT GCCACCGTCG ATCTCCCTCG CCAAAGCTCA TGAGCGCATC 60
AGCCAACATT GGCAAAATCC TGTCGGTGAG CTCAATATCG GAGGAAAACG GTATAGAATT 120
ATCGATAATC AAGTGCTGCG CTTGAACCCC CACAGTGGTT TTTCTCTCTT TCGAGAAGGG 180
GTTGGTAAGA TCTTTTCGGG GAAGATGTTT AACTTTTCAA TTGCTCGTAA CCTTACTGAG 240
ACACTCCATG CAGCCCAGAA AACGACTTCG CAGGAGCTAA GGTCTGATAT CCCCAATGCT 300
CTCAGTAATC TCTTTGGAGC CAAGCCACAG ACCGAACTGC CGCTGGGTTG GAAAGGGAAG 360
CCTTTGTCAG GAGCTCCGGA TCTTGAAGGG ATGCGAGTGG CTGAAACCGA TAAGTTTGCC 420
CAGCGCGAAA GCCATATTAG TATAATAGAA ACTAAGGATA ATCAGCGGTT CGTGGCTAAG 480
ATTGAACGCT CCATTGCCGA GGGGCATTTG TTCCCAGAAC TGGAGGCTTA TAAACACATC 540
TATAAAACCG CGGCCAAACA TCCTAATCTT GCCAATGTCC ATGGCATGGC TGTGGTGCCA 600
TACGGTAACC GTAAGGAGGA AGCATTGCTG ATGGATGAGG TGGATGGTTC GCGTTCTTCT 660
GACACACTAA GAAGCCTCCC CGATAGCTGG AAGCAACGAA ACATCAATAG TGAAGCCTAC 720
TGGGGAACGA TCAAGTTTAT TGCCCATCGG CTATTAGATG TAACCAATCA CCTTGCCAAG 780
GCAGGGATAG TACATAACGA TATCAAACCC GGTAATGTGG TATTTGACCG CGCTAGCGGA 840
GAGCCCGTTG TCATTGATCT AGGATTACAC TCTCGTTCAG GGGAACAACC TAAGGGGTTT 900
ACAGAATCCT TCAAAGCGCC GGAGCTTGGA GTAGGAAACC TAGGCGCATC AGAAAAGAGC 960
GATGTTTTTC TCGTAGTTTC AACCCTTCTA CATGGTATCG AAGGTTTTGA GAAAGATCCG 1020
GAGATAAAGC CTAATCAAGG ACTGAGATTC ATTACCTCAG AACCAGCGCA CGTAATGGAT 1080
GAGAATGGTT ACCCAATCCA TCGACCTGGT ATAGCTGGAG TCGAGACAGC CTATACACGC 1140
TTCATCACAG ACATCCTTGG CGTTTCCCCT GACTCAAGAC CTGATTCCAA CGAAGCCAGA 1200
CTCCACGAGT TCTTGAGCGA CGGAACTATT GACGAGGAGT CGGCCAAGCA GATCCTAAAA 1260
GATACTCTAA CCGGAGAAAT GAGCCCATTA TCTACTGATG TAAGGCGGAT AACACCCAAG 1320
AAGCTTCGGG AGCTCTCTGA TTTGCTTAGG ACGCATTTGA GTAGTGCAGC AACTAAGCAA 1380
TTGGATATGG GGGTGGTTTT GTCGGATCTT GATACCATGT TGGTGACACT CGACAAGGCC 1440
GAACGCGAGG GGGGAGTAGA CAAGGATCAG TTGAAGAGTT TTAACAGTTT GATTCTGAAG 1500
ACTTACAGCG TGATTGAAGA CTATGTCAAA GGCAGAGAAG GGGATACCAA GAGTTCCAGT 1560
GCGGAAGTAT CCCCCTATCA TCGCAGTAAC TTTATGCTAT CGATCGCCGA ACCTTCACTG 1620
CAGAGGATCC AAAAGCATCT GGACCAGACA CACTCTTTTT CTGATATCGG TTCACTAGTG 1680
CGCGCACATA AGCACCTGGA AACGCTTTTA GAGGTCTTAG TCACCTTGTC ACCGCAAGGG 1740
CAGCCCGTGT CCTCTGAAAC CTACAGCTTC CTGAATCGAT TAGCTGAGGC TAAGGTCACC 1800
TTGTCGCAGC AATTGGATAC TCTCCAGCAG CAGCAGGAGA GTGCGAAACG GCAACTATCT 1860
ATTCTGATTA ATCGTTCAGG TTCTTGGGCC GATGTTGCTC GTCAGTCCCT GCAGCGTTTT 1920
GACAGTACCC GGCCTGTAGT GAAATTCGGC ACTGAGCAGT ATACCGCAAT TCACCGTCAG 1980
ATGATGGCGG CCCATGCAGC CATTACGCTA CAGGAGGTAT CGGAGTTTAC TGATGATATG 2040
CGAAACTTTA CAGCGGACTC TATTCCACTA CTGATTCGAC TTGGACGAAG CAGTTTAATA 2100
GATGAGCATT TGGTTGAACA GAGAGAGAAG TTGCGAGACG TGACGACCAT CGCCGAGCGA 2160
CTGAACCGGT TGGAGCGGGA ATGGATGTGA 2190
<210> 38
<211> 31
<212> DNA
<213> Yersinia bacteria
<400)> 38
AAACTGCAGA TGTCTCTTGA GCAGAGGAGT C 31
<210> 39
<211>
<212> DNA
<213> Yersinia bacteria
<400> 39
AAACTGCAGT CAGACTCCCT CTTCCTCCTC 30
...
Claims (51)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/036,582 | 1998-03-06 | ||
| US09/036,582 US5965381A (en) | 1998-03-06 | 1998-03-06 | Delivery of proteins into eukaryotic cells with recombinant yersinia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1304442A true CN1304442A (en) | 2001-07-18 |
Family
ID=21889413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99805875A Pending CN1304442A (en) | 1998-03-06 | 1999-03-03 | Protein Delivery into Eukaryotic Cells Using Recombinant Yersinia |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US5965381A (en) |
| EP (1) | EP1058723A1 (en) |
| JP (1) | JP2002508939A (en) |
| CN (1) | CN1304442A (en) |
| AU (1) | AU2850199A (en) |
| CA (1) | CA2322665A1 (en) |
| HK (1) | HK1038382A1 (en) |
| WO (1) | WO1999045098A2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001431A (en) * | 2014-05-21 | 2017-08-01 | 巴塞尔大学 | Bacteria-based protein delivery |
| CN108472348A (en) * | 2015-11-19 | 2018-08-31 | 巴塞尔大学 | Attenuated bacteria for treating malignant entity tumor |
| CN110325545A (en) * | 2016-12-20 | 2019-10-11 | 巴塞尔大学 | Attenuated bacteria-based protein delivery |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0668350B2 (en) * | 1994-02-16 | 2008-12-03 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma |
| US20040156861A1 (en) * | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
| US6265215B1 (en) * | 1996-09-13 | 2001-07-24 | Ludwig Institute For Cancer Research | Isolated peptides which complex with HLA-Cw16 and uses thereof |
| US6025470A (en) * | 1997-06-23 | 2000-02-15 | Ludwig Institute For Cancer Research | Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof |
| AU5209399A (en) | 1998-07-10 | 2000-02-01 | Cornell Research Foundation Inc. | Recombinant constructs and systems for secretion of proteins via type iii secretion systems |
| WO2001042267A1 (en) * | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| AU2002249917A1 (en) | 2001-01-04 | 2002-08-12 | Yale University | Induction of immune responses to isoaspartyl-modified antigens |
| AU2002312778A1 (en) * | 2001-03-26 | 2002-10-08 | Universite Catholique De Louvain | Type iii bacterial strains for use in medicine |
| GB0112687D0 (en) | 2001-05-24 | 2001-07-18 | Microbiological Res Authority | Pharmaceutical use of secreted bacterial effector proteins |
| US7247297B2 (en) * | 2001-09-14 | 2007-07-24 | The University Of Chicago | Use of DF3/MUC1 regulated expression in gene therapy |
| US7381557B2 (en) * | 2003-04-07 | 2008-06-03 | Tufts University | Compositions and methods for bacterial immunity and secretion of proteins |
| FR2862312B1 (en) | 2003-11-13 | 2006-02-17 | Univ Grenoble 1 | TOOL FOR TRANSFER AND PRODUCTION OF PROTEINS USING THE PSEUDOMONAS TYPE III SECRETION SYSTEM |
| US20060068469A1 (en) * | 2004-08-17 | 2006-03-30 | Research Development Foundation | Bacterial vector systems |
| EP1888634A2 (en) | 2005-05-13 | 2008-02-20 | Oxford Biomedica (UK) Limited | Mhc class i and ii peptide antigens derived from tumour antigen 5t4 |
| US8802419B2 (en) | 2006-03-02 | 2014-08-12 | University Of Massachusetts | Modified pathogens for use as vaccines |
| WO2008148068A1 (en) * | 2007-05-23 | 2008-12-04 | Mannkind Corporation | Multicistronic vectors and methods for their design |
| ES2331271B1 (en) * | 2007-06-29 | 2010-10-14 | Universidad Del Pais Vasco | METHOD FOR THE INTERNALIZATION OF NON INVASIVE BACTERIA IN EUCARIOT CELLS. |
| CA2712511A1 (en) * | 2008-03-17 | 2009-09-24 | Universitaetsklinikum Muenster | Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
| RS61046B1 (en) | 2015-11-19 | 2020-12-31 | Univ Basel | Bacteria-based protein delivery |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU87207A1 (en) * | 1988-04-29 | 1989-11-14 | Univ Louvain | VACCINE DERIVED FROM BACTERIA OF THE GENUS YERSINIA PROCESS FOR ITS PREPARATION AND APPLICATIONS |
| US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| WO1993022423A1 (en) * | 1992-04-29 | 1993-11-11 | Microcarb Inc. | Nutrient phospholipids for pathogenic bacteria |
| US5405940A (en) * | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
| US5530096A (en) * | 1992-12-22 | 1996-06-25 | Ludwig Institute For Cancer Research | Isolated, tyrosinase derived peptides and uses thereof |
| US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
| WO1997040182A1 (en) * | 1996-04-19 | 1997-10-30 | Gabriele Pecher | Genetically transfected human dendritic cells, their production and use, preferably as vaccines |
| US6407063B1 (en) * | 1998-10-02 | 2002-06-18 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
-
1998
- 1998-03-06 US US09/036,582 patent/US5965381A/en not_active Expired - Fee Related
-
1999
- 1999-03-03 HK HK02100105.0A patent/HK1038382A1/en unknown
- 1999-03-03 CA CA002322665A patent/CA2322665A1/en not_active Abandoned
- 1999-03-03 AU AU28501/99A patent/AU2850199A/en not_active Abandoned
- 1999-03-03 CN CN99805875A patent/CN1304442A/en active Pending
- 1999-03-03 WO PCT/IB1999/000587 patent/WO1999045098A2/en not_active Ceased
- 1999-03-03 EP EP99909156A patent/EP1058723A1/en not_active Withdrawn
- 1999-03-03 JP JP2000534630A patent/JP2002508939A/en not_active Withdrawn
- 1999-05-25 US US09/318,141 patent/US6602506B1/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001431A (en) * | 2014-05-21 | 2017-08-01 | 巴塞尔大学 | Bacteria-based protein delivery |
| CN107001431B (en) * | 2014-05-21 | 2022-11-01 | 巴塞尔大学 | Bacteria-based protein delivery |
| CN115960919A (en) * | 2014-05-21 | 2023-04-14 | 巴塞尔大学 | Bacterial-based protein delivery |
| CN108472348A (en) * | 2015-11-19 | 2018-08-31 | 巴塞尔大学 | Attenuated bacteria for treating malignant entity tumor |
| CN110325545A (en) * | 2016-12-20 | 2019-10-11 | 巴塞尔大学 | Attenuated bacteria-based protein delivery |
| CN110325545B (en) * | 2016-12-20 | 2024-02-09 | 巴塞尔大学 | Protein delivery based on attenuated bacteria |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002508939A (en) | 2002-03-26 |
| US5965381A (en) | 1999-10-12 |
| CA2322665A1 (en) | 1999-09-10 |
| WO1999045098A2 (en) | 1999-09-10 |
| US6602506B1 (en) | 2003-08-05 |
| AU2850199A (en) | 1999-09-20 |
| WO1999045098A3 (en) | 1999-12-23 |
| HK1038382A1 (en) | 2002-03-15 |
| EP1058723A1 (en) | 2000-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1304442A (en) | Protein Delivery into Eukaryotic Cells Using Recombinant Yersinia | |
| AU730296B2 (en) | Bacterial vaccines comprising auxotrophic, attenuated strains of (listeria) expressing heterologous antigens | |
| US5830702A (en) | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response | |
| US7097965B2 (en) | Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein | |
| DK2214701T3 (en) | CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria | |
| JP3320095B2 (en) | Stable purA vectors and their use | |
| CN1650015A (en) | DNA vaccines encoding CEA and CD40 ligands and methods of use thereof | |
| EP0544685A1 (en) | Mycobacterial expression vector | |
| KR20200070405A (en) | Immunogenic Irregular Peptides from Cancer Related Proteins and Methods of Use thereof | |
| US20020123108A1 (en) | Fusion proteins between antigenic amino acid sequences and beta-2- microglobulin | |
| US9187754B2 (en) | Modified Bordetella pertussis strains | |
| MXPA04008287A (en) | Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors. | |
| US6235518B1 (en) | Recombinant immunogenic actinomycetale | |
| CN1830489A (en) | Tumor peptide vaccine based on gastrin-releasing peptide | |
| CN1221285C (en) | Preparation method of genetically engineered nano-vaccine for liver cancer, gastric cancer and breast cancer malignant tumors | |
| Paterson | Rational approaches to immune regulation | |
| CN1863552A (en) | Tyrosinase mutants and methods of use thereof | |
| JP2025536332A (en) | Cell surface overexpression technology using the cell outer membrane lipoprotein PrsA expression system | |
| JPH06508741A (en) | Mycobacterial expression vector | |
| CN1294193A (en) | Human Fb65L2-2 protein and polynucleotide sequence to code it | |
| CN1319432A (en) | Broad-spectrum gene engineering nanometer vaccine for treating malignant tumour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1038382 Country of ref document: HK |